No Data
No Data
No Data
Axovant Gene Therapies: FDA Lifts Clinical Hold on AXO-AAV-GM2
DJ Axovant Gene Therapies: FDA Lifts Clinical Hold on AXO-AAV-GM2 By Chris Wack Axovant Gene Therapies Ltd. said Monday the U.S. Food and Drug Administration has lifted its clinical hold and c
68 Biggest Movers From Friday
Gainers Aurora Cannabis Inc. (NYSE:ACB) shares jumped 56.1% to close at $9.79 on Friday after voters in multiple US states voted in favor of legalizing recreational and/or medical marijuana. The Bide
Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM2 for Tay-Sachs and
Axovant Gene Therapies Ltd. (NASDAQ:AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it has received Rare Pediatric Disease Designat
Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosi
NEW YORK, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ:AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it
Axovant Announces Positive Six-Month Follow-Up Data From Second Cohort of SUNRISE-PD Phase 2 Trial o
AXO-Lenti-PD was well-tolerated with no treatment-related serious adverse events at 6 months• 21-point mean improvement in UPDRS Part III “OFF” score, a 40% improvement from baseline, exceeding pre-de
Axovant Gene Therapies Reports 3-Year Clinical Supply Deal With Oxford Biomedica For Manufacturing,
Axovant Gene Therapies Ltd (NASDAQ:AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, announced today that its subsidiary has signed a three-year Clinical
No Data